Panacea Biotec Limited

NSE PANACEABIO.NS

Panacea Biotec Limited Cash and Short-Term Investments for the year ending March 31, 2024: USD 18.74 M

Panacea Biotec Limited Cash and Short-Term Investments is USD 18.74 M for the year ending March 31, 2024, a -36.33% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Panacea Biotec Limited Cash and Short-Term Investments for the year ending March 31, 2023 was USD 29.43 M, a -59.49% change year over year.
Panacea Biotec Limited Cash and Short-Term Investments for the year ending March 31, 2022 was USD 72.65 M, a 438.23% change year over year.
Panacea Biotec Limited Cash and Short-Term Investments for the year ending March 31, 2021 was USD 13.50 M, a 84.25% change year over year.
Panacea Biotec Limited Cash and Short-Term Investments for the year ending March 31, 2020 was USD 7.33 M, a 233.00% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NSE: PANACEABIO.NS

Panacea Biotec Limited

CEO	Dr. Rajesh Jain Ph.D.
IPO Date	July 1, 2002
Location	India
Headquarters	B-1 Extension/G-3
Employees	1,936
Sector	Healthcare
Industries Vaccines Biotechnology Pharmaceuticals Plastics

Description

Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. It also exports its products to over 30 countries worldwide, including the United States, Germany, the Russian Federation, Sri Lanka, the Philippines, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.

Key trends

Past 5 years